DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...

Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug ...

Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...

Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

In a report released today, Miki Sogi from Bernstein maintained a Buy rating on Astellas Pharma (ALPMF – Research Report), with a price target ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...